Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. [electronic resource]
Producer: 20130110Description: 3666-76 p. digitalISSN:- 1529-0131
- Adolescent
- Adult
- Aged
- Antibodies, Antinuclear -- blood
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antibodies, Neutralizing -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Genome-Wide Association Study
- Humans
- Immunoglobulin G -- administration & dosage
- Injections, Intravenous
- Interferons -- genetics
- Lupus Erythematosus, Systemic -- drug therapy
- Male
- Middle Aged
- Placebos
- Severity of Illness Index
- Transcriptome
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.